https://www.accesswire.com/747419/New-Research-More-Than-Half-of-IBS-Patients-Surveyed-Report-Waiting-More-Than-One-Year-Before-Discussing-IBS-Symptoms-With-Their-Healthcare-Provider
Putting to work our deep global technology relationships and intelligence, combined with additional research using strategic and fitment filters, will result in us presenting a shortlist of compatible best-fit partners or targets for your corporate strategy teams to act on. Analyst Block Hours IBSi’...
Microsoft Partner with 20+ Years of Microsoft Dynamics Navision & Business Central experience. Deep expertise across manufacturing, distribution, and more.
New Research Study Concludes That Chronic Abdominal Pain, or IBS – Affecting 15% of Children in the U.S. – is Widely Mistreated With AntidepressantsNEWSEducation
We don't know exactlywhat causes IBS, which means therapeutic options are limited, mostly directed at treating the symptoms rather than targeting specific causes. We also don't have a way to tell who is at increased risk of IBS. In this climate,our general researchaims to identifygenetic ris...
many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development...
such as military personnel. The study was based on data from the Centers for Disease Control and other research studies. The model projects that 9 percent of those with a genetic predisposition would contract IBS after 10 years. However, among high risk groups such as deployed military, 9 perc...
Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower gastrointestinal tract. Most current first-line therapies for IBS and other FBDs target the predominant symptom and mainly a
Always investing in new research for its historic ingredient, the acacia fiber, Nexira releases a new trial on human showing the benefit of inavea™ PURE ACACIA on transit modulation and its extreme tolerability on sensitive people with IBS.
Research on the GM in the gut–bone axis has yielded novel insights into the pathogenesis of OP and the potential for using gut microbes as a treatment strategy. However, the inconsistency of test environments, the host’s genetic backgrounds, and the sources of gut microbes pose significant ch...